PHARMeMED - Latest News, Events, Publications & Opportunities
Latest News
GSK’s RSV vaccine granted FDA priority review for use in adults aged 50 to 59 years: GSK has announced that its respiratory syncytial virus (RSV) vaccine has been accepted for priority review by the US Food and Drug Administration (FDA) for use in adults aged 50 to 59 years who are at an increased risk for RSV disease.If approved, Arexvy would be the first vaccine available to help protect this patient population. Read
Astrazeneca says Catalent deal shows need for in-house capacity: The sale of listed contract drugmaker Catalent?(CTLT.N),?to the parent of Novo Nordisk?(NOVOb.CO),?this week demonstrates the importance for big pharma companies of building an independent supply chain, Astrazeneca?(AZN.L), said Thursday. Read
Researchers suggest erectile dysfunction drugs could reduce risk of Alzheimer’s: Researchers from University College London (UCL) have suggested that drugs used to treat erectile dysfunction could also be linked to a reduced risk of developing Alzheimer’s disease (AD). Read
Researchers discover new cell that remembers allergies: Researchers with McMaster University and Denmark-based pharmaceutical company ALK-Abello A/S have made a groundbreaking discovery: a new cell that remembers allergies.The discovery gives scientists and researchers a new target in treating allergies and could lead to new therapeutics. The research,?published?in?Science Translational Medicine, coins the brand-new cell as a type-2 memory B cell (MBC2). Read
AstraZeneca to invest $300M in new US cell therapy plant: AstraZeneca is expanding its US manufacturing footprint to accelerate its ambitions in next-gen cell therapy discovery and development. A $300m state-of-the-art facility in Rockville, Maryland will be used to launch its life-saving cell therapy platforms in the US for critical cancer trials and future commercial supply. Read
Brainomix’s AI-enabled stroke software endorsed by NICE: The National Institute of Health and Care Excellence (NICE) has issued guidance endorsing the use of Brainomix’s artificial intelligence (AI)-enabled software, Brainomix 360, to help clinical decision-making in strokes. Read
MHRA approves argenx’s subcutaneous generalised myasthenia gravis therapy: The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised a new subcutaneous (SC) formulation of argenx’s Vyvgart (efgartigimod alfa) for generalised myasthenia gravis (gMG). Read
New heart treatment to help grow replacement heart valves in the body: Researchers at Harefield Hospital and Imperial College London’s (ICL) National Heart and Lung Institute have suggested a new heart procedure to help the body grow replacement heart valves.The treatment is developed to produce a living valve in the body that would be able to grow with the patient. Read
Novartis expands oncology pipeline with €2.7bn MorphoSys acquisition: Novartis has announced that it will be acquiring MorphoSys for €2.7bn, marking a significant boost to the drugmaker’s oncology pipeline.The deal gives Novartis access to pelabresib (CPI-0610), an investigational therapy being evaluated in combination with Incyte’s Jakafi (ruxolitinib) as a treatment for myelofibrosis. Read
Sanofi guarantees employees one year of salary and support after cancer diagnosis: CEO Paul Hudson's vision for the company encompasses a?diversity, equity and inclusion plan - with the newest update guaranteeing employees 1 year of salary and support after cancer diagnosis. Read
Study reveals AI can predict patients’ survival in glioblastoma: Researchers from King’s College London (KCL) have developed an artificial intelligence (AI)-based model that can predict adult brain cancer patients’ rates of survival after receiving radiotherapy treatment. Read
Takeda gains rights to Protagonist’s blood disorder asset in deal worth over $300m: Takeda and Protagonist Therapeutics have entered into a worldwide license and collaboration agreement worth over $300m to develop and commercialise an investigational injectable hepcidin mimetic peptide of the natural hormone hepcidin to treat polycythaemia vera (PV). Read
What's the No. 1 top-selling drug of 2023? Last week Merck reported?a whopping $25 billion sales haul for their PD-1 cancer superstar Keytruda, which appears to be the world’s top-selling drug in 2023. Read
Researchers discover epigenetic status determines metastasis: Scientists from the German Cancer Research Center (DKFZ) and Heidelberg University have investigated in mice how spreading tumor cells behave at the site of metastasis. Some tumor cells immediately start to form metastases. Others leave the blood vessel and may then enter a long period of dormancy. What determines which path the cancer cells take is their epigenetic status. Read
FDA proposes down-classifying most high-risk IVDs: The US Food and Drug Administration (FDA) intends to reclassify most high-risk in-vitro diagnostics (IVDs) from class III devices to class II moderate-risk devices. The agency says the move will ease the burden on IVD sponsors who can use the 510(k) premarket notification pathway instead of the more burdensome premarket approval (PMA) process. Read
New microscopy technique could help diagnose and treat brain tumours: Researchers from the Massachusetts Institute of Technology and Harvard Medical School's Brigham and Women’s Hospital have developed a new microscopy technique to reveal brain tissue cells and structures in greater detail. The high-resolution imaging method could help doctors diagnose and treat patients with brain tumours. Read
AbbVie announces NICE recommendation for blood cancer therapy Tepkinly: AbbVie has announced that Tepkinly (epcoritamab) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat adults with diffuse large B-cell lymphoma (DLBCL), an aggressive form of blood cancer. Read
GSK’s Omjjara approved by MHRA to treat myelofibrosis patients with anaemia: GSK’s Omjjara (momelotinib) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adult myelofibrosis patients with moderate or severe anaemia. Read
AbbVie raises 2027 sales forecast for new immunology drugs to $27 billion: AbbVie Inc beat Wall Street estimates for fourth-quarter profit on Friday, helped by a smaller-than-expected decline in sales of its blockbuster drug, Humira, and strong demand for Botox amid stiff competition. Read
Biogen to discontinue Alzheimer's drug Aduhelm in favour of Eisai-partnered Leqembi: Biogen has announced that it will be discontinuing the development and commercialisation of its Alzheimer's treatment, Aduhelm (aducanumab-avwa).The intravenous drug was approved by the US Food and Drug Administration in June 2021 under the accelerated approval pathway, a decision that faced controversy as many argued that there was insufficient evidence of patient benefit. Read
The three most anticipated drug launches in 2024: Every year Evaluate′s Annual Preview Report introduces the most anticipated drug launches of the year ahead.This year′s choice may make you scratch your head at what Evaluate believes will be the most anticipated drug of 2024. It comes from a biotech that many of us may not have heard of: Karuna Therapeutics. Read
Upcoming Events and Webinars
The evolution of MedTech: Pharma roles and opportunities as MedTech transforms - Webinar [FEB 13 2024]: Join
Breaking Barriers: Advance Health Data Interoperability for Seamless Collaboration in Care Delivery - Webinar [FEB 15 2024]: Join
3rd Real World Evidence & Market Access [February 26-27]: Join
3rd RX - TO - OTC Switch [February 26-27]: Join
Engage payers with patient value to streamline pathways to access - Webinar [FEB 28 2024]: Join
4th Edition of the Middle East Pharmaceutical Risk & Compliance Conference [MAR 07, 2024]: Join
???????????? ?????? ???????? - Philadelphia [March 26-27 2024]: Join
Pharma 2024 - Barcelona [16-18 April 2024]: Join
Digital Health USA 2024 [14-15 MAY, San Diego]: Join
Med Dev day (Medical Devices)[07 - 08 October 2024]: Join
领英推荐
Publications
Latest Jobs
Many of these jobs are not advertised on job boards.
Hello there! ?? It's amazing to see someone so dedicated to spreading crucial news in the medical field. As Hippocrates, the father of medicine said, "Let food be thy medicine and medicine be thy food." Your work truly resonates with this philosophy, nurturing the mind and body with knowledge. Speaking of nurturing, Treegens is all about nurturing our planet and we're thrilled about a unique chance to be part of the Guinness World Record for Tree Planting. ?? Check it out and perhaps join our mission: https://bit.ly/TreeGuinnessWorldRecord Keep inspiring with your updates!
?? "Innovation is the ability to see change as an opportunity, not a threat." - Steve Jobs. Your post captures the ever-evolving world of healthcare perfectly! Let's embrace these updates as opportunities for growth and discovery. ???? #HealthcareInnovation